OptiBiotix Health PLC (LON:OPTI)

OptiBiotix Health PLC (LON:OPTI)


Share Price
84.00 p
Change
0.5 (0.60 %)
Market Cap
£71.77 m
Proactive Investors - Run By Investors For Investors

OptiBiotix Health PLC

OptiBiotix Health PLC is a life sciences company operating in one of the most progressive areas of biotechnological research.

Developing technologies that modulate the human microbiome – the collective genome of the microbes in the body – OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that...

EPIC: OPTI
Market: AIM:OPTI
52-week High/Low: 133.25p / 60.00p
Sector: Health Care, Equipment & Services
Market Cap: £71.77 m
Website: www.optibiotix.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of OptiBiotix Health PLC


OptiBiotix Health PLC Snapshot

The OptiBiotix Difference: Better Science, Better Health

Everything we do is underpinned by strong science, backed by human studies, and supported by key opinion leaders, allowing us to deliver quality ingredients and superior white label food and supplement solutions.

 

SlimBiome
 

Transforming the way weight loss is traditionally approached, SlimBiome® offers a healthy, hunger-free weight management system that is backed by strong scientific principles rather than simply relying on willpower.

An award winning functional ingredient, SlimBiome® promotes the feeling of fullness, helps burn calories by promoting a healthy metabolism and maintains blood sugar levels to prevent overeating. It has been shown to reduce calorie intake by up to 20% and lower food cravings.

SlimBiome®:

  • Suitable for wide ranging uses including snack bars, meal replacement shakes, dairy and bakery products
  • Heat stable in processing
  • Low cost
  • Has no distinguishable taste
  • Can be easily added during product manufacture

LP LDL
 

A true breakthrough in innovative health product development, OptiBiotix’s Lactobacillus plantarumLPLDL® is a next-generation probiotic that aids elements of cardiovascular and wellbeing.

What makes this product so distinctive is its ability to improve blood lipid profiles and blood pressure using probiotic research, a holistic, non-pharmaceutical solution, to transform the way physical health is approached. Whereas high levels of cholesterol are commonly addressed with statins, which are drugs known to be associated with a host of undesirable side effects, LPLDL® offers a natural, scientifically founded alternative with no known side effects.

LPLDL® has been shown in randomised, placebo controlled human intervention studies to deliver tangible health benefits, reducing cardiovascular risk factors and supporting overall heart wellness. These include:

  • Lower total cholesterol by up to 36.7%
  • Lower LDL cholesterol by up to 13.9%
  • Increase HDL cholesterol by up to 4.5%
  • Lower systolic blood pressure by 5.1%
  • Be completely safe and well tolerated

*Independent studies have found LPLDL® to be safe and well tolerated by human subjects.

 

CholBiome
 

Transforming the way cardiovascular health is approached, CholBiome® is a unique food supplement that combines three natural, science-backed ingredients to help maintain healthy levels of cholesterol.

A holistic alternative to pharmaceutical treatments, this innovative product helps to reduce blood pressure and cholesterol to promote overall heart wellness.

 

LPGOS

 

LPGOS is a galactooligosaccharide (GOS) produced by the OptiBiotix LPLDL® strain (LPGOS®)

OptiBiotix believes this creates opportunities to use LPGOS in a wide range of food products and applications to help reduce cardiovascular risk factors and improve health.

Rigorous independent tests have demonstrated that LPGOS® is:

  • Suitable for a wide range of food products
  • Heat Resistant
  • Stable during processing

SweetBiotix

SweetBiotix® are patented, natural, low calorie alternatives to sugar.

Made from natural prebiotic fibres SweetBiotix® are calorie free with a clean flavour profile. Products under development include both intense prebiotic sweeteners and bulk sugar substitutes, suitable for wide range of sugar replacement applications in food and beverages.

An innovative dietary fibre concept, SweetBiotix® have the potential to address public health concerns over the impact of sugar on obesity, with the prospect of replacing ‘unhealthy’ sugars in existing products with low calorie, healthy non-digestible fibres.

How sweet is SweetBiotix®?

The Flavour and Sensory Science Centre at the University of Reading carried out a recent study. Six SweetBiotix® customised oligosaccharides developed from high intensity sweeteners were compared to sucrose. The study used a trained expert panel of ten experienced panellists and demonstrated:

  • The customised oligosaccharides showed sweetness of between 140X and 223X that of sucrose at equivalent concentrations
  • Customised oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness

The global sweetener market, currently dominated by sugar, is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017).

 

The Leadership Team

 

Stephen Patrick O'Hara
CEO / Founder

Per Rehne
Executive Commercial Director

Christina Wood
Executive Sales & Marketing Director

Dr Sofia Kolyda
Research & Development Director

Neil Davidson CBE
Chairman

Dr Gareth Barker
Non-Executive Director

Peter Wennstrom
Non-Executive Director

Sean Christie
Non-Executive Director

 

Shareholder Information

Shares In Issue

As at 16 October 2018, the number of shares in issue was 84,724,363.

Significant Shareholders

As at 16 October 2018, significant shareholders that hold more than 3% of the share capital of OptiBiotix Health Plc, and shareholdings of any other directors are detailed below:

  Number Ordinary Shares %
Stephen O'Hara (Director) 10,103,029 11.92
Finance Yorkshire Seedcorn Fund (FYSCF) 9,449,314 11.15

Stephen O'Hara holds 6,099,135 shares under Option

 

Head Office

OptiBiotix Health Plc.
Innovation Centre
Innovation Way
Heslington
York
Y010 5DG

Nominated Adviser
Cairn Financial Advisers LLP
61 Cheapside
London
EC2V 6AX

Solicitors to the Company as to English law
Turner Parkinson LLP
Hollins Chambers
64a Bridge Street
Manchester
M3 3BA

Reporting Accountants and Auditors
Jeffreys Henry LLP
5-7 Cranwood Street
London
EC1V 9EE

Financial Public Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD

Tel: 020 7933 8780
[email protected]

Broker
finnCap
60 New Broad Street,
London
EC2M 1JJ

Intellectual Property Solicitors
Appleyard Lees
The Lexicon
Mount Street
Manchester
M2 5NT

Registrars
Share Registrars Limited
9 Lion and Lamb Yard
Farnham
GU9 7LL

Columns Including OPTI

VIEW ALL

Market Reports Including OPTI

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use